MIRA
INFORM REPORT
|
Report Date : |
12.11.2011 |
IDENTIFICATION DETAILS
|
Name : |
REAXA LTD. |
|
|
|
|
Registered Office : |
Hexagon Tower Blackley Manchester, M9 8ZS |
|
|
|
|
Country : |
United Kingdom |
|
|
|
|
Financials (as on) : |
31.03.2011 |
|
|
|
|
Date of Incorporation : |
02.09.2003 |
|
|
|
|
Com. Reg. No.: |
04884654 |
|
|
|
|
Legal Form : |
Private Independent |
|
|
|
|
Line of Business : |
Manufacture of basic pharmaceutical products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
United Kingdom |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name and address
Reaxa Ltd.
|
|
|
Business
Description
|
Manufacture of Chemicals, Prods & Man-Ma |
Industry
|
Industry |
Biotechnology and Drugs |
|
ANZSIC 2006: |
1841 - Human Pharmaceutical and Medicinal
Product Manufacturing |
|
NACE 2002: |
2441 - Manufacture of basic pharmaceutical
products |
|
NAICS 2002: |
32541 - Pharmaceutical and Medicine
Manufacturing |
|
UK SIC 2003: |
2441 - Manufacture of basic pharmaceutical
products |
|
US SIC 1987: |
2833 - Medicinal Chemicals and Botanical
Products |
Key Executives
|
Financial Summary
|
||||||||||||||||||||
1 - Profit &
Loss Item Exchange Rate: USD 1 = GBP 0.6433939
2 - Balance Sheet Item Exchange Rate: USD 1 = GBP 0.6238497
Corporate Overview
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Executives Report
|
Directors and Shareholders Report
|
Annual Return Date: 02 Sep 2011 |
|
Individual Directors |
|||||||
|
|
|||||||
|
Name |
Status |
DOB |
Filed Address |
Appointment Date |
Resignation Date |
Summary of Directorships |
|
|
Current |
30 Dec 1979 |
92 Casa Grande, K S Tayabji Marg, |
06 Jan 2011 |
NA |
Current:1 |
|
|
|
Current |
15 Jun 1954 |
92 Casa Grande, K S Tayabji Marg, |
06 Jan 2011 |
NA |
Current:1 |
|
|
|
Previous |
18 Jan 1950 |
Ashcroft Greystoke Drive, |
21 Nov 2007 |
30 Sep 2010 |
Current:1 |
|
|
|
Previous |
05 Feb 1963 |
Moorview 1 Millhouse Street, Shuttleworth, |
28 Jul 2004 |
06 Jan 2011 |
Current:7 |
|
|
|
Previous |
08 Oct 1960 |
36 Woolley Avenue, Poynton, |
07 Sep 2004 |
21 Nov 2007 |
Current:0 |
|
|
|
Previous |
01 Apr 1957 |
K.U.S. Industrial Estate, Manor Lane, |
05 Sep 2005 |
02 Dec 2005 |
Current:18 |
|
|
|
Previous |
20 Jan 1963 |
6 Tudor Way, |
07 Sep 2004 |
21 Nov 2007 |
Current:0 |
|
|
|
Previous |
18 Jul 1965 |
3504 Springbrook Drive, |
02 Dec 2005 |
21 Nov 2007 |
Current:0 |
|
|
|
Previous |
06 Dec 1954 |
33 Hough Lane, |
21 Jun 2005 |
05 Sep 2005 |
Current:1 |
|
|
|
Previous |
29 Aug 1965 |
16 Sutherland Drive, |
21 Jun 2005 |
21 Nov 2007 |
Current:1 |
|
|
|
Previous |
11 Jun 1957 |
7 The Ridings, |
21 Nov 2007 |
06 Jan 2011 |
Current:5 |
|
|
|
Previous |
03 Nov 1946 |
14 Woodfield Road, Middleton, |
07 Sep 2004 |
21 Nov 2007 |
Current:4 |
|
|
|
Previous |
06 Feb 1947 |
Manchester Incubator Building, Grafton Street, |
21 Nov 2007 |
06 Jan 2011 |
Current:0 |
|
|
|
Previous |
NA |
2 The Cenacle, |
02 Sep 2003 |
05 Aug 2004 |
Current:0 |
|
|
|
|
|
||||||
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
Corporate Directors |
|
|
|
There are no corporate directors for this company. |
|
|
|
Individual Secretaries |
|||||||
|
|
|||||||
|
Name |
Status |
DOB |
Filed Address |
Appointment Date |
Resignation Date |
Summary of Directorships |
|
|
Current |
NA |
92 Casa Grande, K S Tayabji Marg, |
06 Jan 2011 |
NA |
Current:1 |
|
|
|
Previous |
14 Mar 1964 |
61 Washway Road, |
05 Aug 2004 |
23 Dec 2004 |
Current:16 |
|
|
|
Previous |
20 Jan 1963 |
6 Tudor Way, |
23 Dec 2004 |
14 Mar 2008 |
Current:0 |
|
|
|
Previous |
11 Jun 1957 |
7 The Ridings, |
14 Mar 2008 |
06 Jan 2011 |
Current:5 |
|
|
|
Previous |
NA |
20 Corner Park, |
02 Sep 2003 |
05 Aug 2004 |
Current:2 |
|
|
|
|
|
||||||
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
Corporate Secretaries |
|
|
|
There are no corporate secretaries for this company. |
|
|
|
Individual Shareholders |
||||||
|
|
||||||
|
Name |
Share Details |
Share Type |
# of Shares |
Share Price (GBP) |
Share Value (GBP) |
% of Total Shares |
|
Reaxa Chemistry Solutions Pvt Ltd |
45666 A Ordinary GBP 0.10 |
A Ordinary |
45,666 |
0.10 |
4,566.60 |
65.74 |
|
Reaxa Chemistry Solutions Pvt Ltd |
23795 Ordinary GBP 0.10 |
Ordinary |
23,795 |
0.10 |
2,379.50 |
34.26 |
|
|
|
|
|
|
|
|
|
Corporate Shareholders |
|
|
|
There are no corporate shareholders for this company. |
|
|
Reaxa Limited Files Patent Application for Microencapsulated
Catalyst-Ligand System Methods of Preparation and Methods of Use Thereof
Indian Patent News
11 March 2011
|
[What follows is
the full text of the article.] New Delhi, March
11 -- UK based Reaxa Limited filed patent application for microencapsulated
catalyst-ligand system, methods of preparation and methods of use thereof.
The inventors are Pears David Alan, Treacher Kevin Edward and Nisar Mohammed. Reaxa Limited
filed the patent application on Feb. 17, 2006. The patent application number
is 827/DELNP/2006 A. The international classification number is B01J 13/02. According to the
Controller General of Patents, Designs & Trade Marks, "A
microencapsulated catalyst-ligand system is prepared by dissolving or dispersing
a catalyst and/or a ligand in a first phase (for example an organic phase),
dispersing the first phase in a second, continuous phase (for example an
aqueous phase) to form an emulsion, reacting one or more microcapsule
wall-forming materials at the interface between the dispersed first phase and
the continuous second phase to form a microcapsule polymer shell
encapsulating the dispersed first phase core and when the first phase
contains only a catalyst or a ligand, treating the microcapsules with the
remaining ligand or catalyst component of the catalyst-ligand system. The
catalyst is preferably a transition metal catalyst and the ligand is
preferably an organic ligand. The encapsulated catalyst-ligand system may be
used for conventional catalysed reactions. The encapsulated catalyst-ligand
system may be recovered from the reaction medium and re-cycled." About the
Company Reaxa, Ltd.
develops products and technologies for the chemical industry. The company's
products include Pd(II) EnCat, encapsulated palladium acetate plus
co-encapsulated ligands; Pd(0) EnCat, encapsulated palladium metal
nanoparticles; Pt(0) EnCat, encapsulated platinum metal nanoparticles; Os
EnCat, encapsulated osmium tetroxide; and Ni EnCat, encapsulated nickel
hydrogenation catalyst. Copyright
Contify.com
|
|
Annual Profit & Loss
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
31-Mar-2011 |
30-Jun-2010 |
30-Jun-2009 |
30-Jun-2008 |
30-Jun-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate
(Period Average) |
0.643394 |
0.633607 |
0.627423 |
0.499214 |
0.517836 |
|
Consolidated |
No |
No |
No |
No |
No |
|
|
|
|
|
|
|
|
Audit Fees |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Directors Remuneration |
- |
0.1 |
- |
- |
- |
|
|
|
Annual Balance
Sheet |
|
Financials in:
USD (mil) |
|
|
31-Mar-2011 |
30-Jun-2010 |
30-Jun-2009 |
30-Jun-2008 |
30-Jun-2007 |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate |
0.62385 |
0.668405 |
0.60722 |
0.502475 |
0.498418 |
|
Consolidated |
No |
No |
No |
No |
No |
|
|
|
|
|
|
|
|
Total Tangible Fixed Assets |
0.0 |
0.0 |
0.1 |
0.1 |
0.2 |
|
Intangible Assets |
0.2 |
0.8 |
2.1 |
2.7 |
3.0 |
|
Total Fixed Assets |
0.2 |
0.8 |
2.1 |
2.8 |
3.1 |
|
Total Stocks |
0.0 |
0.1 |
0.2 |
0.2 |
0.1 |
|
Trade Debtors |
0.6 |
0.1 |
0.2 |
0.3 |
0.2 |
|
Cash and Equivalents |
0.0 |
0.1 |
0.1 |
0.7 |
0.0 |
|
Other Current Assets |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Current Assets |
0.6 |
0.3 |
0.5 |
1.3 |
0.4 |
|
Total Assets |
0.8 |
1.1 |
2.6 |
4.1 |
3.6 |
|
Trade Creditors |
0.7 |
0.3 |
0.4 |
0.6 |
0.5 |
|
Bank Overdraft |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Bank Loan Overdrafts |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Director Loans |
- |
0.1 |
- |
- |
- |
|
Total Short Term Loans |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Other Current Liabilities |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Current Liabilities |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Working Capital |
-0.1 |
-0.1 |
0.0 |
0.6 |
-0.1 |
|
Total Long Term Loans |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Other Long Term Liabilities |
0.0 |
0.3 |
0.5 |
0.0 |
0.0 |
|
Total Long Term Liabilities |
0.0 |
0.3 |
0.5 |
0.0 |
0.0 |
|
Issued Capital |
0.0 |
- |
- |
- |
- |
|
Share Premium Accounts |
8.6 |
8.0 |
7.5 |
8.7 |
6.6 |
|
Retained Earnings |
-8.5 |
-7.6 |
-5.9 |
-5.3 |
-3.6 |
|
Total Reserve |
0.1 |
0.4 |
1.7 |
3.4 |
3.1 |
|
Total Shareholders Funds |
0.1 |
0.5 |
1.7 |
3.4 |
3.1 |
|
Net Worth |
-0.1 |
-0.3 |
-0.4 |
0.7 |
0.1 |
|
|
|
Annual Cash
Flows |
|
Financials in:
USD (mil) |
|
|
31-Mar-2011 |
30-Jun-2010 |
30-Jun-2009 |
30-Jun-2008 |
30-Jun-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate
(Period Average) |
0.643394 |
0.633607 |
0.627423 |
0.499214 |
0.517836 |
|
Consolidated |
No |
No |
No |
No |
No |
|
|
|
|
|
|
|
|
Paid Up Equity |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
|
|
Annual Ratios |
|
|
|
|
|
|
|
31-Mar-2011 |
30-Jun-2010 |
30-Jun-2009 |
30-Jun-2008 |
30-Jun-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
- |
- |
- |
- |
- |
|
Exchange Rate |
- |
- |
- |
- |
- |
|
Consolidated |
No |
No |
No |
No |
No |
|
|
|
|
|
|
|
|
Current Ratio |
0.87 |
0.84 |
1.01 |
1.95 |
0.86 |
|
Liquidity Ratio |
0.85 |
0.58 |
0.64 |
1.62 |
0.56 |
|
Solvency Ratio |
11.55% |
41.06% |
65.01% |
84.11% |
85.86% |
|
Current Debt Ratio |
7.66 |
0.82 |
0.27 |
0.19 |
0.16 |
|
Long Term Debt Ratio |
0.00 |
0.38 |
0.21 |
0.00 |
0.00 |
|
Total Debt Ratio |
7.66 |
1.44 |
0.54 |
0.19 |
0.16 |
|
Debt Asset Ratio |
88.45% |
33.63% |
17.38% |
15.89% |
14.14% |
|
Working Finance |
- |
111.48% |
99.83% |
- |
- |
|
Stock Financing |
-0.16 |
-1.62 |
33.10 |
0.35 |
-2.05 |
|
Fixed Asset Investment |
0.23 |
0.72 |
0.82 |
0.69 |
0.88 |
|
Shareholder Liquidity |
- |
1.62 |
3.69 |
- |
- |
|
Stock to Total Assets |
5,573.96% |
1,136.92% |
1,552.52% |
1,913.93% |
2,391.92% |
|
Financial Strength Ratio |
1.73 |
2.03 |
1.92 |
3.57 |
1.42 |
|
Reserve Movement |
-82.26% |
-70.54% |
-40.86% |
12.96% |
-33.93% |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.50.28 |
|
|
1 |
Rs.80.08 |
|
Euro |
1 |
Rs.68.44 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.